The price of Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $9.49 in the last session, down -6.50% from day before closing price of $10.15. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 1417880 shares were traded.
Ratios:
We take a closer look at OCUL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.59 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.90.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on February 09, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On April 21, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $18.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 26 ’24 when SUMMER ROAD LLC bought 930,851 shares for $7.52 per share. The transaction valued at 7,000,000 led to the insider holds 8,591,401 shares of the business.
Mattessich Antony C. sold 18,338 shares of OCUL for $90,773 on Jan 31 ’24. The President and CEO now owns 427,943 shares after completing the transaction at $4.95 per share. On Jan 31 ’24, another insider, Ozden Rabia Gurses, who serves as the Chief Medical Officer of the company, sold 7,764 shares for $4.95 each. As a result, the insider received 38,432 and left with 92,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1.41B and an Enterprise Value of 1.30B. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.14 while its Price-to-Book (P/B) ratio in mrq is 11.97. Its current Enterprise Value per Revenue stands at 22.21 whereas that against EBITDA is -19.54.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.31, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is 7.27, while the 200-Day Moving Average is calculated to be 4.67.
Shares Statistics:
According to the various share statistics, OCUL traded on average about 2.08M shares per day over the past 3-months and 2.81M shares per day over the past 10 days. A total of 148.63M shares are outstanding, with a floating share count of 130.32M. Insiders hold about 12.32% of the company’s shares, while institutions hold 45.06% stake in the company. Shares short for OCUL as of Feb 29, 2024 were 4.74M with a Short Ratio of 2.28, compared to 3.96M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.12% and a Short% of Float of 4.37%.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.2, while EPS last year was -$0.39. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.13 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.51 and -$0.95 for the fiscal current year, implying an average EPS of -$0.68. EPS for the following year is -$0.81, with 5 analysts recommending between -$0.61 and -$1.01.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $15.38M. It ranges from a high estimate of $16.5M to a low estimate of $14.4M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $13.37M, an estimated increase of 15.00% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $76M, while the lowest revenue estimate was $62.87M, resulting in an average revenue estimate of $68.04M. In the same quarter a year ago, actual revenue was $58.44M, up 16.40% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $85M in the next fiscal year. The high estimate is $116M and the low estimate is $70.4M. The average revenue growth estimate for next year is up 24.90% from the average revenue estimate for this year.
